Pulmonary toxicity of nickel subsulfide in F344/N rats exposed for 1-22 days.
Repeated inhalation of nickel subsulfide (Ni3S2) by F344/N rats for 3 months results in chronic active inflammation in the lung and atrophy of the olfactory epithelium. The primary purpose of this study was to determine early responses of the respiratory tract to inhaled Ni3S2 in rats and to track the course of development of such lesions in rats exposed for up to 22 days. A secondary purpose was to obtain an improved estimate of the half-time for clearance of Ni from Ni3S2-exposed lungs. Groups of F344/N rats were exposed to 0, 0.6 or 2.5 mg Ni3S2/m3, 6 h/day for 1-22 days. Histopathological changes in nose and lung, as well as biochemical and cytological changes in lung, as measured in bronchoalveolar lavage fluid (BALF) and lung tissue, alveolar macrophage (AM) viability and Ni concentration in lung were evaluated. Inflammatory lung lesions in rats exposed to 2.5 mg Ni3S2/m3 peaked in intensity after 4 days of exposure. Minimal degeneration of the olfactory epithelium was noted in the 2.5 mg Ni3S2/m3-exposed rats after day 4 of exposure, with atrophy of the olfactory epithelium occurring in rats killed at 22 days. Lactate dehydrogenase, beta-glucuronidase and total protein in BALF were significantly elevated within 7 days of exposure while alkaline phosphatase activity was significantly depressed. AM viability was significantly reduced after 2 days of exposure. Concentrations of Ni in lung increased rapidly during the first 7 days of exposure, but more slowly thereafter. Lung burden data from this and a previous study suggest a clearance half-time for Ni of 3.5-8 days. Results indicate that Ni3S2 is relatively soluble in lung and inhalation of concentrations near the current Threshold Limit Value of 1 mg Ni/m3 can produce detrimental changes in the respiratory tract of rats after only a few days of exposure.
Benson
J M
JM
Inhalation Toxicology Research Institute, Albuquerque, NM 87185, USA.
Cheng
Y S
YS
Eidson
A F
AF
Hahn
F F
FF
Henderson
R F
RF
Pickrell
J A
JA
D000280:Administration, Inhalation; D000336:Aerosols; D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D002273:Carcinogens / Q000008:administration & dosage / Q000633:toxicity*; D002470:Cell Survival / Q000187:drug effects; D004848:Epithelium / Q000187:drug effects / Q000473:pathology; D005260:Female; D005966:Glucuronidase / Q000378:metabolism; D005978:Glutathione / Q000032:analysis; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008168:Lung / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D016676:Macrophages, Alveolar / Q000166:cytology / Q000187:drug effects; D008297:Male; D009532:Nickel / Q000008:administration & dosage / Q000378:metabolism / Q000633:toxicity*; D009929:Organ Size / Q000187:drug effects; D011506:Proteins / Q000032:analysis; D051381:Rats; D011916:Rats, Inbred F344
D000336:Aerosols; D002273:Carcinogens; D011506:Proteins; D009532:Nickel; D007770:L-Lactate Dehydrogenase; D000469:Alkaline Phosphatase; D005966:Glucuronidase; D005978:Glutathione; C017557:nickel subsulfide